New data on how Lemtrada (alemtuzumab) and Aubagio (teriflunomide) perform in a real-world setting will be the focus of Sanofi Genzyme when the company showcases its research at the upcoming 7th Joint ECTRIMS-ACTRIMS Meeting in Paris this week.
Researchers will also share information about the safety of a new investigational therapy, GLD52 (GZ402668), currently in a Phase 1 safety study.
“Lemtrada and Aubagio play important roles in the treatment of relapsing MS, and we look forward to presenting new long-term and real-world data at ECTRIMS to help deepen the MS community’s understanding of these two therapies,” Tom Snow, global head of multiple sclerosis for Sanofi Genzyme, said in a press release.
“In addition, we are continuously working to advance MS treatment and care with research efforts focused on unmet needs for relapsing and progressive forms of the disease,” Snow added.
The TOPAZ study (NCT02255656) is one of the main data sources for the upcoming presentations. The study, which follows relapsing MS patients who participated in the CARE MS-I and CARE MS-II extension study (NCT00930553), is a rich source of information on long-term outcomes.
Researchers will share various aspects of disease outcomes and magnetic resonance imaging (MRI) data from patients followed up to seven years, with some presentations focusing solely on those who switched from treatment with interferon beta-1a.
Among the Lemtrada highlights are findings demonstrating that Lemtrada does not appear to trigger birth defects.
Another presentation compared Lemtrada to Genentech’s Ocrevus (ocrelizumab) using a model that evaluated both the cost and effectiveness of the two drugs. The analysis suggests that Lemtrada more effectively treated relapsing MS and was also linked to lower costs over a 20-year period.
Aubagio studies also focused on long-term patient data, including in people with progressive forms of relapsing MS. Data from the Phase 3 TEMSO (NCT00134563), TOWER (NCT00751881), and the TEMSO extension (NCT00803049) showed that Aubagio stabilized disability progression in these patients over nearly a decade.
Other presentations homed in on Aubagio’s ability to slow brain tissue loss and improve cognitive outcomes.
Finally, Sanofi Genzyme shared initial data on its investigational antibody GLD52. The treatment is an updated form of Lemtrada, which scientists believe gives rise to fewer and milder infusion-related reactions.
Data from the Phase 1 study (NCT02282826), so far indicated that this might indeed be the case, as no severe reactions occurred in the 44 progressive MS patients in the trial.
For a complete list of Sanofi Genzyme’s presentations at the meeting, visit this link.